We are live on ! Find out more
NVS icon

Novartis

920 hedge funds and large institutions have $21.7B invested in Novartis in 2017 Q2 according to their latest regulatory filings, with 84 funds opening new positions, 308 increasing their positions, 361 reducing their positions, and 58 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 2040 (+20)

59% more call options, than puts

Call options by funds: $65M | Put options by funds: $40.8M

45% more first-time investments, than exits

New positions opened: 84 | Existing positions closed: 58

9% more capital invested

Capital invested by funds: $19.9B → $21.7B (+$1.87B)

1% more funds holding

Funds holding: 909920 (+11)

0.26% less ownership

Funds ownership: 11.36%11.09% (-0.26%)

15% less repeat investments, than reductions

Existing positions increased: 308 | Existing positions reduced: 361

Holders
920
Holders Change
+11
Holders Change %
+1.21%
% of All Funds
22.94%
Holding in Top 10
40
Holding in Top 10 Change
+20
Holding in Top 10 Change %
+100%
% of All Funds
1%
New
84
Increased
308
Reduced
361
Closed
58
Calls
$65M
Puts
$40.8M
Net Calls
+$24.2M
Net Calls Change
+$61.4M
Name Holding Trade Value Shares
Change
Change in
Stake
AL
501
Aspiriant LLC
California
$867K -$71.5K -1,009 -8%
CTI
502
Community Trust & Investment
Kentucky
$866K -$13.3K -187 -2%
EGA
503
E&G Advisors
Texas
$864K
ZB
504
Zions Bancorporation
Utah
$864K +$753K +10,621 +1,140%
SCM
505
Salem Capital Management
Massachusetts
$858K
Toronto Dominion Bank
506
Toronto Dominion Bank
Ontario, Canada
$857K -$151K -2,126 -16%
HPC
507
HM Payson & Co
Maine
$850K -$4.89K -69 -0.6%
FC
508
Ferris Capital
Massachusetts
$850K +$806K +11,368 New
LPC
509
Loeb Partners Corp
New York
$843K -$3.9K -55 -0.5%
DAC
510
Dividend Assets Capital
South Carolina
$834K -$5.17K -73 -0.7%
NRS
511
Neville Rodie & Shaw
New York
$829K
LWM
512
Lenox Wealth Management
Ohio
$827K +$783K +11,051 New
SAM
513
Shamrock Asset Management
Texas
$825K -$27.5K -388 -3%
BFM
514
Boston Financial Management
Massachusetts
$823K -$59.3K -837 -7%
LDB
515
Lee, Danner & Bass
Tennessee
$823K +$14.2K +201 +2%
CAN
516
Cetera Advisor Networks
California
$819K -$6.95K -98 -0.9%
NHC
517
Nicholas Hoffman & Company
Georgia
$810K +$50K +705 +7%
DSC
518
Duncker Streett & Co
Missouri
$798K +$112K +1,580 +17%
BMC
519
Beaton Management Company
Massachusetts
$798K +$756K +10,666 New
PA
520
Perennial Advisors
New York
$796K +$4.39K +62 +0.6%
BMO
521
Beck Mack & Oliver
New York
$787K
MWM
522
Marietta Wealth Management
Georgia
$786K +$22.5K +317 +3%
EIM
523
Essex Investment Management
Massachusetts
$785K
RCM
524
Riverhead Capital Management
Delaware
$785K
FFS
525
Founders Financial Securities
Maryland
$773K +$732K +10,332 New

NVS Hedge Fund Activity: Q2 2017 in Review

920 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q2 2017, worth a combined $21.7B — up 9.4% from $19.9B a quarter earlier.

Buyers outnumbered sellers: 84 funds opened new NVS positions and 58 closed out — a net gain of 26 holders — while 308 added to existing stakes and 361 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $151M. The largest seller was Federated Hermes, cutting an estimated $166M.

  • 920 institutional investors held Novartis (NVS) as of Q2 2017, up from 909 in Q1 2017.
  • Funds reported $21.7B of Novartis stock for Q2 2017, up 9.4% quarter-over-quarter.
  • 84 funds opened new Novartis positions in Q2 2017 and 58 closed out, a net change of +26 holders.
  • The largest Novartis buyer in Q2 2017 was Janus Henderson Group, an estimated $151M added.
  • The largest Novartis seller in Q2 2017 was Federated Hermes, an estimated $166M sold.

Based on aggregated 13F filings for Q2 2017.